RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
A new hair loss treatment theory beyond minoxidil and finasteride is proposed, causing mixed reactions in the community, with some members eager to explore and support it, while others call for more research and evidence.
The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.
An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.
Whether topical caffeine can be as effective for hair growth as minoxidil and finasteride, with various replies discussing the efficacy of these treatments and criticism of Dr. Huberman's research methods.
A 25-year-old is experiencing chronic telogen effluvium (TE) and androgenetic alopecia (AGA) after surgery, using finasteride, red light therapy, and supplements, and considering oral minoxidil despite heart concerns. They are unsure whether to start minoxidil before or after an upcoming surgery, which may trigger another hair shed.
The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.